Indaptus Therapeutics, Inc.
INDP
$1.73
-$0.03-1.71%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 369.61% | -50.61% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 207.94% | -40.57% | |||
| Operating Income | -207.94% | 40.57% | |||
| Income Before Tax | -172.68% | 43.10% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -172.68% | 43.10% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -172.68% | 43.10% | |||
| EBIT | -207.94% | 40.57% | |||
| EBITDA | -207.95% | 40.58% | |||
| EPS Basic | -51.29% | 67.19% | |||
| Normalized Basic EPS | -51.29% | 67.19% | |||
| EPS Diluted | -51.29% | 67.19% | |||
| Normalized Diluted EPS | -51.29% | 67.19% | |||
| Average Basic Shares Outstanding | 80.24% | 73.42% | |||
| Average Diluted Shares Outstanding | 80.24% | 73.42% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||